Oral PrEP will reach women who need it if PrEP programs are well-supported and prepared. A collaboration between LVCT Health in Kenya and AVAC, through the USAID-funded OPTIONS Consortium, this video series shows how LVCT Health made changes at the site level and helped women interested in oral PrEP overcome recurring barriers to uptake and adherence.
Each film in the series highlights a different theme or challenge that emerged as PrEP rolled out, and tells the story of how the project responded–and has an accompanying commentary as well. This series is intended to foster innovation and problem-solving among key PrEP stakeholders, including program implementers, policy makers, civil society, advocates and people considering PrEP.
Issue: Women find it difficult to come to a clinic for oral PrEP services because of stigma. Additionally, taking
medicine for prevention is not a common practice.
Key Findings: Testing in the community, reaching women where they access family planning or other services,
and peer to peer encouragement increased the number of women accessing oral PrEP.
Issue: Women are more likely to start and continue oral PrEP if clinics offer an accommodating and welcoming
Key Findings: Integrated services, sensitized staff, adjusted clinic hours, support groups and hotline numbers
encouraged women to take up and stay on oral PrEP.
Issue: Women who begin oral PrEP often do not continue after the first month due to side effects, stigma, and the burden of a daily pill.
Key Findings: Programs can minimize drop off during month one with continuous communication, easy access to staff and support groups.
Issue: Men often have the power to decide if a woman uses oral PrEP.
Key Findings: Programs trying to reach women need to actively engage men who act as “gatekeepers” for women considering starting oral PrEP.
The US Food and Drug Administration has expanded the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV to include adolescents. Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.
New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP started taking the drug within 30 days — according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.
Australia's federal government has announced it will list an effective HIV prevention drug on the Pharmaceutical Benefits Scheme (PBS), starting next month. Health Minister Greg Hunt today confirmed that pre-exposure prophylaxis, known as PrEP, would be government subsidized from April 1.